Slide 1: Your Vote Is Extremely Important: Vote the WHITE Proxy Card
YOUR VOTE IS EXTREMELY IMPORTANT VOTEThE WhITE PROXY CARd FOR DIRECTORS COMMITTED TO DELIVERING SHAREHOLDER VALUE!
Slide 2: Forward-Looking and Proxy Solicitation Statements
FORWARd LOOkINgANd PROXY SOLICITATION TATEMENTS This presentation includes forward-looking statements about: our 2009 guidance and our financial and operational goals through the anticipated development and timing of programs in our clinical pipeline the sales potential of TYSABRI R Each forward-loo
Slide 3: Delivering on Our Commitment to Shareholders
DELIVERINGONOUR COMMITMENT TO ShAREhOLdERS Consistently delivered strong EPS and FINANCIAL 2008 results exceeded guidance PERFORMANCE Solid growth projected for 2009; Q1 revenues Continuing to grow TYSABRI and effectively OPERATIONAL Viewed as having one of the most robust PERFORMANCE Progress in pi
Slide 4: Consistently Delivered on the Biogen Idec Merger Goals
CONSISTENTLY TRONg S TRACk ECORD DElIVEREDONThE BIOgEN IDEC ERgERgOAlS M REVENUE EPS FREE CASh FLOW ( $Billions) ($) ($ Millions) +7% 4.___+5% 3.66 +37% _,89 CAGR CAGR CAGR 3.2 2.74 2.7 2.25 737 2.2 2.4 1.9 571 643 1.40 1.57 1.22 367 03 04 05 06 07 08 03 04 05 06 07 08 04 05 06 07 08 Note: 2003 amou
Slide 5: Product Revenues
PROdUCT REVENUES ($ in millions)+4% _,03 CAGR 1,707 1,868 AVONEX 1,417 1,543 1,169 Leading MS Therapy 03 04 05 06 07 08 ($ in millions) +8% _,8 CAGR 926 811 RITUXAN 709 616 Standard of Care for NHL 493 03 04 05 06 07 08 ($ in millions) +305% 589 CAGR TYSAbRI Powerful Efficacy 230 36 06 07 08 Note: 2
Slide 6: Substantial Progress Over the Past Year Toward 2010 Goals
00 WEMADE SUbSTANTIALPROgRESS OVERTHEPAST GOALS YEARTOWARDACHIEVINGOUR 2010GOALS gOAL PROgRESS REVENUEgROwTh 15% top line CAGR from 2007 to+ FINANCIAL EPSgROwTh 20% bottom line CAGR from 2007 to + TYSABRI R TYSABRI patients on therapy — AVONEX maintains its patient AVONEX R in the “ABCR” market PROd
Slide 7: Biogen Idec Board Has Owners' Perspective, Steward of Shareholder Value
BIOGEN IDEC BOARDOF DIRECTORS hAS OWNERS’ERSPECTIVE STEWARdOF ShAREhOLdER VALUE Largest merger of 2 independent biotechs $3B share repurchase/Dutch Auction Disciplined execution of business development strategy Review of strategic alternatives; including sale of the company STRONg CORPORATEgOVERNANC
Slide 8: Biogen Idec Board Has Broad-Based Experience
BIOGEN IDEC BOARD hASbROAdbASEd XPERIENCE CUSTOMER NObEL LAUREATE gENERAL FINANCE / NTERNATIONAL PUbLIC R&d PERSPECTIVE / / NATL CAdEMY MANAgEMENT M&A bUSINESS POLICY MARkET &ALES OF CIENCES larry Best* Alanglassberg, M.D.* Robert Pangia* Bill Young* Jim Mullen Bruce Ross Phil Sharp, Ph.D. lynn Sche
Slide 9: Conclusion
CONCLUSION biogen Idec has a proven track delivering exceptional performance The business is poised to create Pursuing a well-defined strategy for future Broad and deep pipeline with 8 late stage programs expected by year end 2009 Theboard is best positioned to deliver value to our shareholders Acti
Slide 10: GAAP to Non-GAAP Reconciliation: Diluted EPS and Net Income
gAAPTONON-gAAP R ECONCILIATIONDILUTED EPS AND NET INCOME TTRIBUTABLETO BIOGEN IDEC INC. Condensed Consolidated Statements basis of Income Operating (unuadited, $ in millions, except per share amounts) FY003 FY004 FY005 FY006 FY007 FY008 GAAP diluted EPS (4.92) 0.07 0.47 0.63 1.99 2.65 Adjustment to
Slide 11: Protect Your Investment: Please Vote the WHITE Proxy Card
PROTECT YOUR Please Vote WhITE the Proxy Card dAY! Instructions for voting your shares by telephone, along with your WHITE proxy card and postage- We urge you NOT to gold proxy card sent to you byreturn any If you need assistance in voting your shares by please contact Innisfree M&A Incorporated, wh